<DOC>
	<DOCNO>NCT02668783</DOCNO>
	<brief_summary>The purpose study ass etonogestrel ( ENG ) + 17β-estradiol ( E2 ) vaginal ring 's efficacy compare placebo vaginal ring treatment dysmenorrhea Treatment Cycle 2 . In addition , study assess safety tolerability ENG-E2 vaginal ring . Primary hypothesis : Relative placebo ring , ENG-E2 vaginal ring result great proportion participant ≥3 point reduction peak pelvic pain score increase number rescue pain relief ( ibuprofen ) tablets take Treatment Cycle 2 compare baseline .</brief_summary>
	<brief_title>Efficacy Safety Etonogestrel + 17β-Estradiol Vaginal Ring ( MK-8342B ) Women With Primary Dysmenorrhea ( With Optional Extension ) ( MK-8342B-059 )</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Postmenarcheal female , age ≤50 year , good physical mental health . History moderate severe primary dysmenorrhea past 3 month longer , history recurrent nonmenstrual pelvic pain intermittently continuously throughout month , history dysmenorrhea secondary structural pelvic pathology . Body mass index ( BMI ) ≥18 &lt; 38 kg/m^2 . History regular menstrual cycle cycle length 24 32 day ( inclusive ) past three month . Willing adhere use vaginal ring require trial procedure , plan relocate study . Willing use rescue medication ibuprofen study recommend dose pain medication treatment dysmenorrhea . Cardiovascular risk disorder , include history venous thromboembolic [ VTE ] event , arterial thrombotic thromboembolic [ ATE ] event , transient ischemic attack , angina pectoris , claudication ; high risk VTE event due recent prolonged immobilization , plan surgery require prolonged immobilization , hereditary acquire predisposition elevate risk venous arterial thrombosis ; currently smoke us tobacco/nicotine contain product ≥35 year age ; uncontrolled severe hypertension ; history severe dyslipoproteinemia ; &lt; 35 year age history migraine aura focal neurological symptom ≥35 year age history migraine without aura focal neurologic symptom ; diabetes mellitus endorgan involvement &gt; 20 year duration ; multiple cardiovascular risk factor ≥35 year age , obesity , inadequately control hypertension , use tobacco/ nicotine product , inadequately control diabetes . Gynecologic condition : surgically sterilize , use hormonal contraceptive ( pill , patch , ring , implant , intrauterine system ) within past 3 month , currently use nonhormonal intrauterine device ( IUD ) ; within past 6 month undiagnosed ( unexplained ) abnormal vaginal bleeding abnormal vaginal bleeding expect recur study ; gonorrhea , chlamydia , trichomonas symptomatic vaginitis/cervicitis ; abnormal cervical smear positive highrisk human papillomavirus ( HPV ) test screening document within 3 year screen ; Stage 4 pelvic organ prolapse ( 1 cm beyond introitus ) less degree prolapse history difficulty retain tampon , vaginal ring , product within vagina . Gastrointestinal urologic disorder , include history pancreatitis associate severe hypertriglyceridemia ; clinically significant liver disease , include active viral hepatitis cirrhosis ; history gastrointestinal urologic tract may cause pelvic pain . Other medical disorder , include history malignancy ≤5 year prior sign inform consent except adequately treat basal cell squamous cell skin cancer situ cervical cancer ; disease may worsen hormonal treatment disturbance bile flow , systemic lupus erythematosus , pemphigoid gestationis idiopathic icterus previous pregnancy , middleear deafness , Sydenham chorea , porphyria ; know allergy/sensitivity contraindication investigational product excipients ; know allergy/sensitivity contraindication ibuprofen , experience asthma , urticaria , allergictype reaction take aspirin , nonsteroidal antiinflammatory drug ; history drug alcohol abuse dependence . Known suspected pregnancy , pregnant breastfeeding within past 2 month . Has use investigational drug and/or participate clinical trial within past 8 week .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>